Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Recruiting now

Conditions studied: COPD, Emphysema, Asthma COPD Overlap, Emphysema

In brief

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Key facts

Study ID

NCT03263130

Run by

Gelb, Arthur F., M.D.

People needed

60

Starts

2017-01-01

Expected to finish

2027-12-01

Last updated by the study team

2023-10-27

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• asthma- copd overlap
• emphysema in smokers with smoking history > 15 pack years
• COPD/ bronchitis and bronchiectasis in smokers with smoking history
• >15 pack years
• Exclusion Criteria:other pulmonary or systemic diagnosis
• non smokers
• any other pulmonary diagnosis
• pulmonary fibrosis

Where it is running

• Arthur F Gelb MD — Lakewood, California, United States (enrolling)
• Arthur F Gelb MD — Lakewood, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.